MaxCyte Historical Balance Sheet

MXCT Stock

USD 4.16 0.03 0.72%

Trend analysis of MaxCyte balance sheet accounts such as Total Current Liabilities of 9.7 M provides information on MaxCyte's total assets, liabilities, and equity, which is the actual value of MaxCyte to its prevalent stockholders. By breaking down trends over time using MaxCyte balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining MaxCyte latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether MaxCyte is a good buy for the upcoming year.

MaxCyte Inventory

12.84 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.

About MaxCyte Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of MaxCyte at a specified time, usually calculated after every quarter, six months, or one year. MaxCyte Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of MaxCyte and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which MaxCyte currently owns. An asset can also be divided into two categories, current and non-current.

MaxCyte Balance Sheet Chart

At this time, MaxCyte's Cash And Short Term Investments are comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 281.7 M in 2024, despite the fact that Net Debt is likely to grow to (26.4 M).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of MaxCyte assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in MaxCyte books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on MaxCyte balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of MaxCyte are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from MaxCyte's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into MaxCyte current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.At this time, MaxCyte's Cash And Short Term Investments are comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 281.7 M in 2024, despite the fact that Net Debt is likely to grow to (26.4 M).

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	5.7M	16.1M	18.7M	19.7M
Total Assets	284.1M	286.7M	268.3M	281.7M

Short Long Term Debt Total Total Assets

MaxCyte balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Stockholder Equity	Other Liab	Net Tangible Assets
Total Assets		0.83	0.93	0.86	1.0	0.93	0.83	-0.64	-0.92	-0.4	0.81	0.82	0.45	0.98	0.8	0.9	0.84	0.9	0.95	0.91	0.99	-0.38	0.79	0.95	0.83	0.99
Short Long Term Debt Total	0.83		0.94	0.75	0.81	0.96	0.66	-0.42	-0.95	-0.36	0.7	0.94	0.26	0.73	0.68	0.75	0.99	0.97	0.87	0.97	0.75	-0.34	0.68	0.75	0.96	0.85
Other Current Liab	0.93	0.94		0.88	0.92	0.95	0.83	-0.62	-0.99	-0.37	0.83	0.9	0.33	0.87	0.78	0.86	0.95	0.98	0.91	0.99	0.88	-0.42	0.83	0.87	0.9	0.92
Total Current Liabilities	0.86	0.75	0.88		0.86	0.79	0.95	-0.64	-0.89	-0.26	0.76	0.65	0.26	0.86	0.87	0.96	0.78	0.8	0.84	0.86	0.87	-0.45	0.96	0.94	0.68	0.81
Total Stockholder Equity	1.0	0.81	0.92	0.86		0.91	0.83	-0.64	-0.9	-0.4	0.8	0.8	0.47	0.99	0.79	0.89	0.81	0.88	0.94	0.89	0.99	-0.37	0.78	0.95	0.81	0.99
Property Plant And Equipment Net	0.93	0.96	0.95	0.79	0.91		0.71	-0.46	-0.95	-0.49	0.71	0.94	0.44	0.85	0.72	0.84	0.95	0.98	0.93	0.96	0.86	-0.3	0.7	0.86	0.97	0.94
Current Deferred Revenue	0.83	0.66	0.83	0.95	0.83	0.71		-0.57	-0.81	-0.2	0.68	0.51	0.2	0.86	0.93	0.9	0.71	0.7	0.83	0.8	0.87	-0.59	0.94	0.88	0.57	0.75
Net Debt	-0.64	-0.42	-0.62	-0.64	-0.64	-0.46	-0.57		0.64	-0.1	-0.94	-0.52	-0.09	-0.64	-0.37	-0.53	-0.43	-0.56	-0.41	-0.57	-0.63	0.25	-0.65	-0.59	-0.36	-0.63
Retained Earnings	-0.92	-0.95	-0.99	-0.89	-0.9	-0.95	-0.81	0.64		0.32	-0.84	-0.9	-0.29	-0.84	-0.77	-0.87	-0.95	-0.98	-0.89	-0.99	-0.86	0.36	-0.84	-0.87	-0.89	-0.91
Accounts Payable	-0.4	-0.36	-0.37	-0.26	-0.4	-0.49	-0.2	-0.1	0.32		-0.05	-0.43	-0.86	-0.36	-0.15	-0.42	-0.3	-0.42	-0.39	-0.31	-0.36	0.02	-0.05	-0.39	-0.52	-0.45
Cash	0.81	0.7	0.83	0.76	0.8	0.71	0.68	-0.94	-0.84	-0.05		0.75	0.17	0.76	0.53	0.68	0.7	0.8	0.64	0.8	0.77	-0.31	0.75	0.73	0.63	0.81
Non Current Assets Total	0.82	0.94	0.9	0.65	0.8	0.94	0.51	-0.52	-0.9	-0.43	0.75		0.39	0.7	0.48	0.68	0.9	0.96	0.77	0.9	0.72	-0.14	0.55	0.72	0.96	0.87
Non Currrent Assets Other	0.45	0.26	0.33	0.26	0.47	0.44	0.2	-0.09	-0.29	-0.86	0.17	0.39		0.44	0.18	0.45	0.19	0.36	0.36	0.25	0.44	0.17	0.09	0.44	0.46	0.5
Cash And Short Term Investments	0.98	0.73	0.87	0.86	0.99	0.85	0.86	-0.64	-0.84	-0.36	0.76	0.7	0.44		0.82	0.89	0.74	0.8	0.93	0.83	1.0	-0.42	0.8	0.95	0.72	0.95
Net Receivables	0.8	0.68	0.78	0.87	0.79	0.72	0.93	-0.37	-0.77	-0.15	0.53	0.48	0.18	0.82		0.87	0.74	0.68	0.87	0.78	0.83	-0.47	0.9	0.84	0.6	0.7
Common Stock Shares Outstanding	0.9	0.75	0.86	0.96	0.89	0.84	0.9	-0.53	-0.87	-0.42	0.68	0.68	0.45	0.89	0.87		0.76	0.81	0.89	0.84	0.9	-0.3	0.87	0.97	0.73	0.85
Non Current Liabilities Total	0.84	0.99	0.95	0.78	0.81	0.95	0.71	-0.43	-0.95	-0.3	0.7	0.9	0.19	0.74	0.74	0.76		0.96	0.89	0.98	0.77	-0.4	0.74	0.77	0.93	0.83
Inventory	0.9	0.97	0.98	0.8	0.88	0.98	0.7	-0.56	-0.98	-0.42	0.8	0.96	0.36	0.8	0.68	0.81	0.96		0.87	0.98	0.82	-0.29	0.73	0.82	0.95	0.91
Other Current Assets	0.95	0.87	0.91	0.84	0.94	0.93	0.83	-0.41	-0.89	-0.39	0.64	0.77	0.36	0.93	0.87	0.89	0.89	0.87		0.91	0.94	-0.43	0.77	0.92	0.85	0.92
Total Liab	0.91	0.97	0.99	0.86	0.89	0.96	0.8	-0.57	-0.99	-0.31	0.8	0.9	0.25	0.83	0.78	0.84	0.98	0.98	0.91		0.85	-0.43	0.82	0.84	0.91	0.9
Total Current Assets	0.99	0.75	0.88	0.87	0.99	0.86	0.87	-0.63	-0.86	-0.36	0.77	0.72	0.44	1.0	0.83	0.9	0.77	0.82	0.94	0.85		-0.42	0.81	0.96	0.74	0.96
Short Term Debt	-0.38	-0.34	-0.42	-0.45	-0.37	-0.3	-0.59	0.25	0.36	0.02	-0.31	-0.14	0.17	-0.42	-0.47	-0.3	-0.4	-0.29	-0.43	-0.43	-0.42		-0.5	-0.34	-0.22	-0.3
Common Stock	0.79	0.68	0.83	0.96	0.78	0.7	0.94	-0.65	-0.84	-0.05	0.75	0.55	0.09	0.8	0.9	0.87	0.74	0.73	0.77	0.82	0.81	-0.5		0.85	0.58	0.71
Other Stockholder Equity	0.95	0.75	0.87	0.94	0.95	0.86	0.88	-0.59	-0.87	-0.39	0.73	0.72	0.44	0.95	0.84	0.97	0.77	0.82	0.92	0.84	0.96	-0.34	0.85		0.74	0.92
Other Liab	0.83	0.96	0.9	0.68	0.81	0.97	0.57	-0.36	-0.89	-0.52	0.63	0.96	0.46	0.72	0.6	0.73	0.93	0.95	0.85	0.91	0.74	-0.22	0.58	0.74		0.86
Net Tangible Assets	0.99	0.85	0.92	0.81	0.99	0.94	0.75	-0.63	-0.91	-0.45	0.81	0.87	0.5	0.95	0.7	0.85	0.83	0.91	0.92	0.9	0.96	-0.3	0.71	0.92	0.86

Click cells to compare fundamentals

MaxCyte Account Relationship Matchups

MaxCyte balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	30.0M	51.8M	284.1M	286.7M	268.3M	281.7M
Short Long Term Debt Total	7.2M	7.0M	5.7M	16.1M	18.7M	19.7M
Other Current Liab	3.6M	5.2M	6.5M	8.3M	9.7M	10.2M
Total Current Liabilities	9.3M	11.6M	15.6M	15.4M	17.9M	9.7M
Total Stockholder Equity	13.6M	33.2M	262.9M	254.0M	232.2M	243.8M
Property Plant And Equipment Net	5.5M	6.5M	13.4M	33.6M	34.8M	36.5M
Current Deferred Revenue	3.2M	4.8M	6.7M	6.7M	5.1M	3.5M
Net Debt	(8.0M)	(11.8M)	(42.1M)	5.0M	(27.8M)	(26.4M)
Retained Earnings	(83.4M)	(95.2M)	(114.3M)	(137.9M)	(175.8M)	(167.0M)
Accounts Payable	2.1M	890.2K	1.8M	292K	743K	705.9K
Cash	15.2M	18.8M	47.8M	11.1M	46.5M	48.8M
Non Current Assets Total	5.5M	6.5M	13.7M	34.4M	78.1M	82.0M
Cash And Short Term Investments	16.7M	34.8M	255.0M	227.3M	168.3M	176.7M
Net Receivables	3.2M	5.2M	6.9M	11.2M	5.8M	4.3M
Common Stock Shares Outstanding	56.4M	69.5M	90.6M	101.7M	103.3M	66.8M
Liabilities And Stockholders Equity	30.0M	51.8M	284.1M	286.7M	268.3M	281.7M
Non Current Liabilities Total	7.0M	6.9M	5.6M	17.3M	18.3M	19.2M
Inventory	3.7M	4.3M	5.2M	8.6M	12.2M	12.8M
Other Current Assets	797.1K	1.0M	3.3M	6.0M	3.9M	4.1M
Total Liab	16.4M	18.6M	21.2M	32.7M	36.1M	37.9M
Total Current Assets	24.5M	45.3M	270.4M	252.3M	190.2M	199.7M
Short Term Debt	508.9K	672.6K	527.2K	157K	1.5M	845.8K
Common Stock	574K	773.8K	1.0M	1.0M	1.0M	542.8K
Other Stockholder Equity	96.4M	127.7M	376.2M	390.8M	406.9M	222.4M
Other Liab	338.1K	646.6K	450.2K	1.3M	1.5M	1.6M
Net Tangible Assets	13.6M	33.2M	262.9M	254.0M	292.1M	306.7M
Common Stock Total Equity	574K	773.8K	1.0M	1.0M	1.2M	807.8K
Capital Lease Obligations	2.3M	2.0M	5.7M	16.1M	18.7M	19.7M
Net Invested Capital	18.5M	38.1M	262.9M	254.0M	232.2M	133.2M
Property Plant And Equipment Gross	5.5M	6.5M	7.7M	23.7M	45.0M	47.3M
Non Current Liabilities Other	338.1K	646.6K	450.2K	1.3M	283K	268.9K
Net Working Capital	15.1M	33.6M	254.8M	236.8M	172.3M	118.2M
Property Plant Equipment	5.5M	6.5M	13.4M	23.7M	27.3M	28.6M
Short Term Investments	1.5M	16.0M	207.3M	216.3M	121.8M	103.8M
Capital Stock	574K	773.8K	1.0M	1.0M	1.0M	905.1K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MaxCyte Historical Balance Sheet

MaxCyte Inventory

12.84 Million

About MaxCyte Balance Sheet Analysis

MaxCyte Balance Sheet Chart

Total Assets

Total Current Liabilities

MaxCyte balance sheet Correlations

MaxCyte Account Relationship Matchups

High Positive Relationship

High Negative Relationship

MaxCyte balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for MaxCyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Other Current Liab

Total Liab	- 0.99	Retained Earnings
Retained Earnings	- 0.99	Other Current Liab
Inventory	- 0.98	Retained Earnings
Non Current Liabilities Total	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Property Plant And Equipment Net
Retained Earnings	- 0.95	Short Long Term Debt Total